IO Biotech Inc

IOBT | $1.435 -0.35% -0.35% 59K

(0.0% 1d) (-16.8% 1m) (-23.6% 1y) (0.0% 2d) (0.0% 3d) (-4.0% 7d) (-14.55% volume)
Earnings Calendar:
Market Cap: $ 94,539,112
https://www.iobiotech.com
Sec Filling | Patents | 2021 employees

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark.

cancer t-cell

add to watch list Paper trade email alert is off

Press-releases

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
IOBT | $1.435 -0.35% -0.35% 59K

| -7.1% | O: 0.65% H: 1.92% C: -3.21%
biotech commercialization

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K

| -8.28% | O: 1.91% H: 2.5% C: 0.63%
io102 biotech cancer

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
Published: 2024-04-05 (Crawled : 12:30) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K

| -15.79% | O: -0.58% H: 0.0% C: -5.88%
LLY | News | $745.06 1.88% 0.0% 2M

Health Technology

| -6.42% | O: -2.06% H: 2.77% C: 2.45%
biotech business

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K

| -13.25% | O: 5.42% H: 1.71% C: 1.14%
biotech association cancer research meeting

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K

| -11.11% | O: -6.79% H: 13.91% C: 9.93%
biotech results

IO Biotech to Present at 44th Annual Cowen Health Care Conference
Published: 2024-02-26 (Crawled : 21:00) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K

| -7.1% | O: 0.65% H: 5.77% C: 1.92%
conference biotech health care

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
Published: 2023-12-21 (Crawled : 13:30) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K

| -2.7% | O: 2.03% H: 1.99% C: -3.31%
first biotech tumor trial

IO Biotech Announces 2023 Third Quarter Results
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K

| 55.04% | O: -10.5% H: 22.7% C: 14.3%
biotech results

IO Biotech Appoints Helen Collins, MD, to its Board of Directors
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K

| 55.04% | O: -10.5% H: 22.7% C: 14.3%
biotech

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K

| 53.01% | O: -4.36% H: 4.42% C: 3.19%
melanoma biotech trial

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000905148-24-000970	4	2024-03-18	2024-03-15	Buy	A	750000	750000
0000905148-24-000969	4	2024-03-18	2024-03-15	Buy	A	280000	280000